A systematic review of randomised controlled trials has examined whether previous biologic therapy affects the efficacy of upadacitinib in inflammatory bowel disease (IBD), addressing a key question for clinicians positioning newer oral agents within treatment pathways. The analysis, published in Cureus, sought to clarify how prior exposure to biologic therapies influences outcomes with the Janus kinase (JAK) inhibitor in both Crohn’s disease and ulcerative colitis.
Background Context
Upadacitinib is an oral JAK1 inhibitor approved for moderate to severe ulcerative colitis and Crohn’s disease in patients who have responded inadequately to conventional or biologic therapy. As treatment algorithms in IBD have become increasingly complex, with multiple biologic classes available, understanding how prior therapy exposure affects subsequent treatment efficacy has become essential for informed clinical decision making. Biologic-experienced patients often represent a more refractory population, and their response to newer agents may differ from biologic-naive cohorts. The positioning of JAK inhibitors relative to anti-TNF therapies and newer biologics targeting interleukin pathways remains an evolving area of clinical practice.
Key Findings
The authors searched PubMed/MEDLINE, ScienceDirect, Scopus and ClinicalTrials.gov from inception to January 2026, following PRISMA 2020 and with the protocol registered prospectively on PROSPERO. Eligible studies were Phase 3 randomised controlled trials in moderate-to-severe ulcerative colitis or Crohn’s disease that reported subgroup data by biologic exposure status. Three studies covering six Phase 3 programmes met the criteria, all judged at low overall risk of bias. Because the data were not pooled, the synthesis is narrative rather than a meta-analysis.
Response rates were numerically lower in patients with prior biologic exposure, but upadacitinib retained a therapeutic benefit in every subgroup examined. In Crohn’s disease, stratified risk differences for clinical remission consistently favoured upadacitinib over placebo, ranging from 14.5 to 33.0 percentage points. Biologic-naive patients achieved numerically higher remission rates, but biologic-experienced patients retained meaningful clinical and endoscopic benefit at one year. In ulcerative colitis, upadacitinib was superior to placebo across all primary endpoints.
On safety, the review found a dose-dependent increase in adverse events during the maintenance phase at 30 mg compared with 15 mg, including herpes zoster and elevated liver enzymes.
Clinical Relevance
For gastroenterologists managing complex IBD cases, the practical message is that prior biologic failure lowers the expected remission rate with upadacitinib but does not remove the benefit, which supports its use as a salvage option after one or more biologics have failed. That framing is useful for setting realistic expectations in shared decision making with patients who have extensive treatment histories.
Two caveats apply. The review is narrative rather than a meta-analysis, drawing on only three studies, so the risk differences quoted are not pooled estimates. And the dose-dependent safety signal at 30 mg versus 15 mg in maintenance, particularly herpes zoster and hepatic enzyme elevation, is relevant when weighing dose escalation in a biologic-experienced patient. Upadacitinib belongs to the JAK inhibitor class, which carries a regulatory boxed warning (FDA and MHRA) for major cardiovascular events, blood clots, cancer and death; the authors call for head-to-head trials to clarify positioning.
Reference
Htun M, Lilhori A, Alamgir M, Al-Shemary M, Sriram R, Azeez N, Rajbhandari P, Muratova A, Patil S, Godavarthy PK, Mahmood A, Kylanathan J, Teli A. Impact of Prior Biologic Exposure on Upadacitinib Efficacy in Inflammatory Bowel Disease: A Systematic Review of Randomized Controlled Trials. Cureus. 2026;18(7):e113539. doi:10.7759/cureus.113539
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.